{"id":"arm-1-oral-cortico-steroids","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Infection (increased susceptibility)"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Corticosteroids enter cells and bind to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and alter transcription of pro-inflammatory genes. This results in decreased production of cytokines, chemokines, and adhesion molecules, leading to broad immunosuppression and anti-inflammatory effects across multiple tissues.","oneSentence":"Oral corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:27:38.852Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune conditions (specific indication not detailed in study arm description)"},{"name":"Immunosuppression in clinical research settings"}]},"trialDetails":[{"nctId":"NCT01326494","phase":"PHASE4","title":"Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-04","conditions":"Upper Respiratory Tract Infection, Asthma","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prednisone"],"phase":"marketed","status":"active","brandName":"Arm 1 Oral Cortico Steroids","genericName":"Arm 1 Oral Cortico Steroids","companyName":"University of British Columbia","companyId":"university-of-british-columbia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression. Used for Inflammatory and autoimmune conditions (specific indication not detailed in study arm description), Immunosuppression in clinical research settings.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}